NSE IPO - Apply Online, Check Issue Date, Price, Lot Size & Allotment Status

Apply for NSE IPO:

Skip to main content

Live Obsidian Therapeutics, Inc. Common Stock Share Price Chart

O H L

Obsidian Therapeutics, Inc. Common Stock Performance Overview

Days Range
$17.47Low
$17.77High

Markets Today

Previous Close$17.50
Open$17.77
Volume36,352
Day's Range$17.47 - $17.77
52W RangeNA
Market Cap$1.06 B

Historical Performance

1M Returns-12.28
3M ReturnsNA
6M ReturnsNA
1Y ReturnsNA
5Y ReturnsNA
10Y ReturnsNA

Obsidian Therapeutics, Inc. Common Stock Fundamentals

Market Cap$1.06 B
Dividend yieldN/A
PE RatioN/A
PEG RatioN/A
RevenueN/A
ROE TTMN/A
EPS TTMN/A
Quarterly Earnings Growth YOYN/A
PB RatioN/A
EBITDAN/A
Profit MarginN/A
Market Cap$1.06 B
Dividend yieldN/A
PE RatioN/A
PEG RatioN/A
RevenueN/A
ROE TTMN/A
EPS TTMN/A
Quarterly Earnings Growth YOYN/A
PB RatioN/A
EBITDAN/A
Profit MarginN/A

Obsidian Therapeutics, Inc. Common Stock Return Calculator

The Obsidian Therapeutics, Inc. Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$10,000
Invested Amount$10,000
Est. Returns$0
Invest in USA Stock Today

About Obsidian Therapeutics, Inc. Common Stock

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

FAQs

Obsidian Therapeutics, Inc. Common Stock (OBX) share price as of September 18, 2026 is $17.11. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Obsidian Therapeutics, Inc. Common Stock (OBX) Share by opening an international trading account with Angel One.
Purchasing Obsidian Therapeutics, Inc. Common Stock (OBX) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Obsidian Therapeutics, Inc. Common Stock (OBX) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Obsidian Therapeutics, Inc. Common Stock (OBX) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Obsidian Therapeutics, Inc. Common Stock on September 18, 2026, is $1.06 B.
Obsidian Therapeutics, Inc. Common Stock operates in the null sector, specifically in the null industry.
In order to invest in Obsidian Therapeutics, Inc. Common Stock (OBX) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.

Diversify Your Portfolio with US Stocks

Invest in Wall Street Giants from India

+91
Top US Stocks

VIEW ALL

Open Free Demat Account!

Join our 3.8 Cr+ happy customers
+91